# **Major Resources Table**

In order to allow validation and replication of experiments, all essential research materials listed in the Methods should be included in the Major Resources Table below. Authors are encouraged to use public repositories for protocols, data, code, and other materials and provide persistent identifiers and/or links to repositories when available. Authors may add or delete rows as needed.

## Animals (in vivo studies)

Species	Vendor or Source	Background Strain	Sex	Persistent ID / URL
C57BL6/J	Jackson Laboratories	C57BL6/J	Μ	000664
C57BL6/J	Jackson Laboratories	C57BL6/J	F	000664
Db/db mice	Jackson Laboratories	C57BL6/J	M/F	000697

#### **Genetically Modified Animals**

	Species	Vendor or Source	Background Strain	Other Information	Persistent ID / URL
Parent - Male					
Parent - Female					

#### Antibodies

Target antigen	Vendor or Source	Catalog #	Working	Lot # (preferred	Persistent ID / URL
			concentration	but not required)	
CD68	Invitrogen	MA5-13324	1:1000		
IL1b	Cell Signal	31202	1:1000		Clone D6D6T
Alpha SMA	Dako	M0851	1:100		Clone 1A4
VWF	Dako	A0082	1:100		
IL1b Neutralizing	BioXCell	BE0246	1 mg/ml		100 microgram per
Ab					dose injected
Isotype Ab for IL1b	BioXCell	BE0091	1 mg/ml		100 microgram per
					dose injected
F4/80 Neutralizing	BioXcell	BE0206	1 mg/ml		100 microgram per
ab					dose injected
Isotype Ab for	BioXCell	BE0090	1 mg/ml		100 microgram per
F4/80					dose injected
Hashing Abs for sc-	Biolegend	B0301-	1:100		1:100 dilution in
RNA-Seq		B0304			100 microliters of
					1e6 cells
Donkey anti-	Thermo/Invitrogen	A16017	1:5000		
mouse IgG HRP					
conjugated					
Donkey anti-rabbit	Thermo/Invitrogen	A16023	1:5000		
IgG HRP					
conjugated					

## **DNA/cDNA Clones**

Clone Name	Sequence	Source / Repository	Persistent ID / URL

## **Cultured Cells**

	Name	Vendor or Source	Sex (F, M, or unknown)	Persistent ID / URL
--	------	------------------	------------------------	---------------------

## Data & Code Availability

Description	Source / Repository	Persistent ID / URL	
Single cell sequencing process code	Website	https://github.com/kropskilab/myeloid_il1b	

#### Other

Description	Source / Repository	Persistent ID / URL	
Clodronate + PBS Liposomes	Liposoma	Batches: C29E0622, P20E0522	
PBS Liposomes			

#### **ARRIVE GUIDELINES**

The ARRIVE guidelines (<u>https://arriveguidelines.org/</u>) are a checklist of recommendations to improve the reporting of research involving animals. Key elements of the study design should be included below to better enable readers to scrutinize the research adequately, evaluate its methodological rigor, and reproduce the methods or findings.

#### **Study Design**

Groups	Sex	Age	Number (prior	Number (after	Littermates	Other description
			to experiment)	termination)	(Yes/No)	
Group 1	M/F	8 weeks	9	9	NA	Directly purchased from
(Control)						Jackson and sacrificed
						at day 0
Group 2 (L-	M/F	8 weeks	9	9	NA	Directly purchased from
NAME + HFD						Jackson and sacrificed
2 weeks)						after 2 weeks of L-
						NAME in water and high
						fat diet
Group 3 (L-	M/F	8 weeks	9	9	NA	Directly purchased from
NAME/HFD						Jackson and sacrificed
for 5 weeks)						after 5 weeks of L-
						NAME in water and high
						fat diet
Group 4 (L-	M/F	8 weeks	9	9	NA	Directly purchased from
NAME/HFD						Jackson and sacrificed
for 12						after 12 weeks of L-
weeks)						NAME in water and high
						fat diet
Group 5 (L-	M/F	8 weeks	8	8	NA	Directly purchased, but
NAME/HFD						sacrificed for bulk RNA-
for 5 weeks)						seq (n=4) and single cell
						RNA-seq (n=4)
Group 6	M/F	8 weeks	8	8	NA	Directly purchased, but
(control for 5						sacrificed for bulk RNA-
weeks)						seq (n=4) and single cell

						RNA-seq (n=4) after 5
						weeks of normal diet
						and water
Group 7	M/F	8 weeks	8	8	NA	Directly purchased,
(Clodronate						sacrificed afer 5 weeks
+ L-						of clodronate lipsome IP
NAME/HFD)						injection and L-
						NAME/HFD
Group 8 (PBS	M/F	8 weeks	10	10	NA	Directly purchased,
liposome +						sacrificed after 5 weeks
L-						of PBS liposome IP
NAME/HFD)						injection and L-
						NAME/HFD
Group 9	M/F	8 weeks	8	8	NA	Directly purchased,
(IL1b						sacrificed after 5 weeks
injection + L-						of L-NAME/HFD and 2
NAME/HFD)						weeks of IL1b injection
Group 10	M/F	8 weeks	8	8	NA	Directly purchased,
(Isotype						sacrificed after 5 weeks
injection +						of L-NAME/HFD and 2
LNAME/HFD)						weeks of Isotype Ab
						injection
Group 11	M/F	8 weeks	8	8	NA	Directly purchased,
(F4/80 Ab						sacrificed after 5 weeks
Injection +						of L-NAME/HFD and 2
LNAME/HFD)						weeks of F4/80 Ab
						injection
Group 12	M/F	8 weeks	8	8	NA	Directly purchased,
(Isotype Ab +						sacrificed after 5 weeks
LNAME/HFD						of L-NAME/HFD and 2
for F4/80						weeks of Isotype Ab
Ab)						injection for F4/80
Group 14	M/F	24	6	6	NA	Directly purchased and
(db/db mice)		weeks				sacrificed at correct age
Group 15	M/F	24	6	6	NA	Directly purchased as
(C57BL6/J		weeks				control for Group 14
mice)						and sacrificed at correct
						age

Various controls

114 total mice

**Sample Size:** Please explain how the sample size was decided Please provide details of any a *prior* sample size calculation, if done.

Based on prior studies, we aimed to identify a 20% change in outcomes (primary outcome of RV systolic pressure) with underlying 15% variance in measurements between mice. With  $\alpha$  = 0.05, and  $\beta$  = 0.2, we expected a sample size of 8 mice per group to be adequate to detect differences between groups.

DOI [to be added]

#### **Inclusion Criteria**

Inclusion criteria included mice that arrived after purchase from Jackson Laboratories in good and healthy condition, defined by normal physical appearance and activity.

#### **Exclusion Criteria**

No mice were excluded from the study once the study began.

#### Randomization

Mice were randomized by even/odd number into each experimental group after direct purchase

## Blinding

Scientists were not blinded to the experimental group for each mouse.